In 2022, MMIT launched the inaugural Patient Access Awards to recognize manufacturers who are going above and beyond to ensure that much-needed therapies get into the hands of the patients who need them.
The winners—one per therapeutic area—are determined by payer and physician stakeholders, who are surveyed as part of the MMIT quarterly Oncology Index and Biologics and Injectables Index.
In this research, payer and physician stakeholders assess and rank the performance of manufacturers across a series of factors, including the manufacturer’s overall commitment to a disease, account representative support, patient and family support programs and resources, patient copay assistance, physician education, and support and HUB services.
Learn more about MMIT’s Oncology Index and Biologics and Injectables Index
Oncology Winners:
-
Novartis (Breast Cancer)
-
Merck & Co. (Metastatic Melanoma)
-
Bristol-Myers Squibb (Non-Small Cell Lung Cancer)
-
Bristol-Myers Squibb (Bladder Cancer)
Biologics & Injectables Winners:
-
CSL Behring (Hereditary Angioedema)
-
Pfizer, Inc. (Growth Hormone Deficiency)
-
Janssen Pharmaceuticals (Rheumatoid Arthritis)
-
Novartis (Multiple Sclerosis)
Award Methodology
MMIT’s Indices team fields primary research for our Oncology Index and Biologics and Injectables Index reports with our industry-leading panel of payers and physicians to assess the current and emerging trends in a variety of therapeutic areas. In this research, the payers and physician panelists evaluate the pharmaceutical manufacturers within a given therapeutic area on their performance across a series of metrics related to patient access services. The winners of the MMIT Patient Access Award are the pharmaceutical manufacturers—one per therapeutic area—who receive the highest ratings by the panelists.
Upcoming Awards: Q2
The winners for Q2 will be announced in September 2022 and will include manufacturers within the following therapeutic areas: psoriasis, psoriatic arthritis, atopic dermatitis, severe asthma, diabetes, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma and acute myeloid leukemia.
